We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Bayer AG | TG:BAYN | Tradegate | Ordinary Share |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 1.21 | 4.41% | 28.52 | 28.54 | 28.55 | 28.775 | 27.815 | 27.88 | 319,601 | 10:43:01 |
From May 2019 to May 2024
By Michael Dabaie
Evogene Ltd. (EVGN) said its corn disease resistance research collaboration with the Crop Science Division of Bayer AG (BAYN.XE) is being refocused on identifying genome editing targets for evaluation against a broad range of corn diseases.
The amended agreement follows positive results in corn stalk rot fungal disease control, biotechnology company Evogene said.
Evogene shares were up 6.5% premarket, to $1.64.
Evogene will use its Computational Predictive Biology platform to identify the required edits to improve disease resistance in corn. Any promising targets would be pursued by Bayer's in-house team for validation, Evogene said.
The collaboration aims to develop improved corn seeds with resistance to fungal diseases.
Write to Michael Dabaie at michael.dabaie@wsj.com
(END) Dow Jones Newswires
July 16, 2019 07:42 ET (11:42 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
1 Year Bayer Chart |
1 Month Bayer Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
